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Abstract
Recent genome-wide association studies (GWAS) have identified several gene variants associated with sporadic chronic
lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Many of these CLL/SLL susceptibility loci are located in non-
coding or intergenic regions, posing a significant challenge to determine their potential functional relevance. Here, we
review the literature of all CLL/SLL GWAS and validation studies, and apply eQTL analysis to identify putatively functional
SNPs that affect gene expression that may be causal in the pathogenesis of CLL/SLL. We tested 12 independent risk loci for
their potential to alter gene expression through cis-acting mechanisms, using publicly available gene expression profiles
with matching genotype information. Sixteen SNPs were identified that are linked to differential expression of SP140,a
putative tumor suppressor gene previously associated with CLL/SLL. Three additional SNPs were associated with differential
expression of DACT3 and GNG8, which are involved in the WNT/b-catenin- and G protein-coupled receptor signaling
pathways, respectively, that have been previously implicated in CLL/SLL pathogenesis. Using in silico functional prediction
tools, we found that 14 of the 19 significant eQTL SNPs lie in multiple putative regulatory elements, several of which have
prior implications in CLL/SLL or other hematological malignancies. Although experimental validation is needed, our study
shows that the use of existing GWAS data in combination with eQTL analysis and in silico methods represents a useful
starting point to screen for putatively causal SNPs that may be involved in the etiology of CLL/SLL.
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Introduction
Chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL) is the third most common type of non-Hodgkin
lymphoma in Western countries [1], and exhibits one of the
strongest familial aggregations of all malignancies [2]. Four
genome-wide association studies (GWAS) [3,4,5,6] and GWAS
validation studies [7,8,9,10,11,12] have identified several novel low-
penetrance susceptibility alleles associated with sporadic and
familial CLL/SLL. Together, these studies identified 12 indepen-
dent loci in 11 novel susceptibility regions for CLL/SLL at 2q13,
2q37.1, 2q37.3, 6p25.3, 8q24.21, 11q24, 15q23, 15q25.2, 16q24.1,
18q21.1 and 19q13.32 [3,4,6,7,8,9,10,11,12]. With the exception of
rs7169431 on 15q21.3, all original SNPs identified by the initial
GWAS [4,12] were validated either directly or indirectly through
other SNPs in linkage disequilibrium (LD), in at least one of the
other GWAS [3,6] or in other independent, large-scale [7,9,11] or
pooled [8] studies of Caucasian ancestry (Table 1 and Figure 1).
Three of these SNPs, rs872071 (6p25.3, IRF4), rs13397985 (2q37.1,
SP140) and rs17483466 (2q13, ACOXL), also were significantly
associated with CLL/SLL in a Chinese population [10] . Similar to
GWAS in other diseases, many of these CLL/SLL susceptibility loci
are located in non-coding or intergenic regions with unknown
biological relevance. This has prompted the need for a post-GWAS
functional characterization of validated CLL/SLL risk alleles.
Extensive inter-individual differences in gene expression exist in
humans [13] that may account for an important fraction of
phenotypic differences, including susceptibility to complex disor-
ders such as CLL/SLL. Familial aggregation patterns in humans
have unequivocally demonstrated an inherited contribution
towards these phenotypic traits [13]. Loci responsible for this
genetic control are known as expression quantitative trait loci
(eQTL). The identification of eQTL is an emerging area in
genomic studies, particularly with the integration of genome-wide
SNP data and gene expression profiles. Several landmark eQTL
studies in humans have been recently conducted that show that
gene expression can be affected by polymorphisms in cis-o rtrans-
regulatory regions [14] or by exonic variants that alter transcript
stability or splicing [15]. Here, we reviewed the literature for all
CLL/SLL GWAS and validation studies and applied eQTL
analysis to identify putatively functional SNPs that affect gene
expression and may be causal in the pathogenesis of CLL/SLL.
We also conducted in silico functional analysis on these SNPs to
explore the potential associated regulatory mechanisms that may
be involved in CLL/SLL development.
Results
CLL/SLL eQTL analysis
Using publicly available gene expression profile databases [16]
with matching genotype information, we conducted an eQTL
analysis on the 12 known GWAS CLL/SLL SNPs that were
validated in independent studies (depicted in bold in Table 1) and
included SNPs in LD (pairwise r
2$0.8) to test for their potential to
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We identified two previously reported SNPs (rs13397985 and
rs11083846) and 17 novel SNPs in two independent regions that
were significantly associated with altered gene expression,
assuming a threshold of 20% false positive ratio (BH,0.20)
(Table 2 and Figure 2A and B). The minor alleles of 16 of these
SNPs were linked to decreased SP140 expression in the eQTL
analysis. Two SNPs, rs11083846 and rs4802322, were significantly
associated with a higher expression of two distinct genes, DACT3
and GNG8, and rs11670473 was associated with increased DACT3
expression.
Screening for putative functionality of CLL/SLL eQTL
SNPs
Using the in silico prediction tools F-SNP [17] and is-rSNP [18],
we identified 41 putative regulatory elements for 12 of the 16
significant eQTL SNPs associated with altered SP140 expression
and for two of the three eQTL SNPs associated with DACT3 or
GNG8 expression (Table S2). Because variations within evolution-
arily conserved regions are more likely to be associated with gene
expression phenotypes [19,20], we also tested if the eQTL SNPs
were located in genomic regions significantly conserved between
Homo sapiens, Mus musculus or Rattus norvegicus (Table S2). Using the
ECR browser [21], we found six SNPs in evolutionarily conserved
regions (,31.6% of our top eQTL SNPs), as expected based on
prior predictions [19,22]. Predictions for regulatory elements were
found for three of these SNPs (rs13384787, rs9989746, and
rs11670473, Table S2). To test if the functional predictions were
likely to be biologically relevant, we searched the literature for
prior evidence that the predicted regulatory elements were
previously associated with any cancer, hematologic cancers and
CLL/SLL, in particular (Table S2). Out of the 41 regulatory
Table 1. CLL/SLL susceptibility loci identified through genome-wide association studies and follow-up studies.
Risk
locus SNP ID r
2
Chr Pos
GRCh37 (bp)
Major/minor
allele Nearest gene(s) SNP location
OR (risk
allele)
a
(95% CI)
(risk
allele)
a P-trend
a Ref.
Further vali-
dation ref.
2q13 rs17483466 111797458 A/G ACOXL, BCL2L11 Intron 10 of ACOXL 1.39 (1.25–1.53) 2.36E-10 [4] [6,10,11]
2q37.1 rs13397985 231091223 T/G SP140, SP110 Intron 1 of SP140 1.41 (1.26–1.57) 5.40E-10 [4] [6,9,10,11]
2q37.3 rs757978 242371101 G/A FARP2 Exon 9 1.39 (1.25–1.56) 2.11E-09 [12] [6]
rs11681497
b 1 242344333 A/G FARP2 Intron 4 1.38 (1.24–1.54) 4.53E-09 [12]
6p25.3 rs872071 411064 A/G IRF4 39UTR 1.54 (1.41–1.69) 1.91E-20 [4] [3,6,7,9,10,11]
rs9378805
b 0.74 417727 A/C IRF4 ,10 kb from 39UTR 1.51 (1.38–1.65) 4.62E-19 [4] [3,6,9,11]
rs1050979
c 0.99 410417 A/G IRF4 39UTR 1.59 (1.43–1.78) 3.68E-17 [7]
rs9391997
c 0.99 409119 A/G IRF4 39UTR 1.59 (1.42–1.77) 5.61E-17 [7]
rs1050976
c 0.99 408079 C/T IRF4 39UTR 1.58 (1.41–1.76) 2.13E-16 [7]
8q24.21 rs2456449 128192981 A/G – – 1.26 (1.17–1.35) 7.84E-10 [12] [6]
rs2466024
b 0.75 128188019 G/A – – 1.2 (1.12–1.29) 4.60E-07 [12]
11q24.1 rs735665 123361397 G/A GRAMD1B ,50 kb centromeric 1.45 (1.31–1.61) 3.78E-12 [4] [3,6,9,11]
15q23 rs7176508 70018990 G/A – – 1.37 (1.26–1.50) 4.54E-12 [4] [6,9,11]
rs11072110 .0.9 69987882 T/C –– 1.54 (1.24–1.92) 1.00E-04 [11]
rs10220831 .0.9 69992114 C/T/G –– 1.56 (1.25–1.95) 9.00E-05 [11]
rs35707742 .0.9 70004352 G/C –– 1.52 (1.22–1.90) 2.10E-04 [11]
rs4777184 .0.9 70007323 C/T –– 1.52 (1.22–1.89) 2.10E-04 [11]
15q25.2 rs783540
d 83254708 A/G CPEB1 Intron 2 1.17 (1.11–1.24) 1.10E-07 [12] [8]
16q24.1 rs305061 85975659 C/T IRF8 ,19 kb telomeric 1.22 (1.12–1.32) 3.60E-07 [12] [6]
rs305065 0.93 85973866 C/G IRF8 ,17 kb telomeric 0.77 (0.61–0.97) 2.37E-02 [6]
rs391525 85944439 A/G IRF8 Intron 3 0.64 (0.55–0.74) 3.16E-09 [6]
rs305077 0.99 85943466 T/C IRF8 Intron 3 0.66 (0.57–0.77) 3.37E-08 [6]
rs2292980 0.99 85945076 T/C IRF8 Intron 3 0.66 (0.56–0.76) 1.89E-08 [6]
rs2292982 0.99 85944823 T/G IRF8 Intron 3 0.64 (0.55–0.74) 3.16E-09 [6]
18q21.1 rs1036935
d 47843534 C/T CXXC1, MBD1 Telomeric 1.16 (1.09–1.25) 1.30E-05 [12] [8]
19q13.32 rs11083846 47207654 G/A PRKD2, STRN4 Intron 3 of PRKD2 1.35 (1.22–1.49) 3.96E-09 [4] [9]
rs11668878
b 0.27 47268373 G/T FKRP, SLC1A5 Intergenic 1.37 (1.21–1.55) 3.65E-07 [4]
Notes: In regular font are original independent SNPs identified through GWAS. In italics font are SNPs in LD with the original GWAS SNPs. In bold font are independently
validated SNPs used for eQTL analysis and risk alleles as called by the primary study. Nearest gene(s) map within ,200 kb of each SNP.
aOR, CI and P-trend quoted are per copy of risk allele (bold in column 5) from all data combined in the primary study. P-trend, significance of the association between
each SNP and risk of CLL/SLL.
bConditional analysis reportedly provided no evidence for an independent role compared to original SNP [4,7,12].
cAcquired after fine-scale mapping.
dSignificance obtained from combined analysis from refs [12] and [8].
Abbreviations: LD, Linkage disequilibrium; OR, odds ratio; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; CI, confidence interval.
doi:10.1371/journal.pone.0029632.t001
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half have previously been associated with hematologic cancers or
CLL/SLL (see references in Table S2), supporting the biological
plausibility of our findings.
Discussion
Recent GWAS [3,4,5,6] and validation studies [7,8,9,10,11,12]
have identified 12 independent loci associated with CLL/SLL risk.
To further elucidate the functional importance of these and other
CLL/SLL risk alleles, we conducted an eQTL analysis and
applied in silico methods to explore the functional relevance of
independently validated CLL/SLL GWAS SNPs and SNPs in
high LD. Our analyses support the potential functionality of two
previously reported SNPs and identified 17 novel putatively causal
SNPs that either alter SP140, DACT3 or GNG8 gene expression.
We also identified 41 putative regulatory elements that may be
affected by these eQTL SNPs, many of which have been
previously associated with hematologic malignancies or CLL/
SLL.
Factors predicted to alter SP140 expression in CLL/SLL
The SP140 GWAS SNP, rs13397985, and 15 eQTL SNPs in
LD were associated with significantly lower SP140 expression.
SP140 is an appealing candidate for CLL/SLL susceptibility as it is
restricted to lymphoid cells, specifically expressed in all mature B
cells and plasma cell lines [23]. Similar to its homolog, SP100,
SP140 contains a zinc-finger motif and a bromodomain suggesting
that it plays a role in chromatin-mediated regulation of gene
expression [23,24]. Although it is currently unknown which genes
are regulated by SP140, it is possible that SP140 regulates the
expression of genes involved in CLL/SLL development. Homol-
ogy with SP100 also suggests that SP140 may exert tumor
suppressor activity [25]. This may provide a biologically feasible
mechanism for the increased risk of CLL/SLL associated with
reduced SP140 expression. Moreover, as SP140 confers resistance
to viruses [26], it may influence CLL/SLL risk through
modulation of responses to antigenic stimulation.
Twelve of the 16 significant eQTL SNPs associated with altered
SP140 expression were located in potential regulatory elements.
Two of these, rs13384787 and rs9989746, are in evolutionarily
conserved regions. The most relevant findings for rs13384787 and
rs9989746 are the disruption of a potential binding site for NIT2
and decreased binding potential for KLF4, respectively. Both
transcription factors are putative tumor suppressor proteins
[27,28]; thus, a reduction in their binding potential might play a
biologically relevant role in the pathogenesis of CLL/SLL.
Several eQTL SNPs in non-conserved regions are predicted to
alter potential binding sites for regulatory elements that have been
either directly or indirectly implicated in the pathogenesis of CLL/
SLL and other hematological malignancies (See references in
Table S2). Although experimental validation is needed, the tumor
suppressors/pro-apoptotic factors, MZF1 [29] and the ubiquitous
transcription factor STAT1 [30] may be biologically relevant as
decreased binding interactions might lower SP140 expression.
The microarray data used for the eQTL analysis is based on
expression changes in lymphoblastoid cell lines. It is therefore
possible that in vitro conditions may have affected gene expression
levels. Thus, eQTL analyses will need to be followed up using gene
expression data from fresh healthy lymphocytes once available. In
addition, these lymphoblastoid cell lines were generated by
Epstein-Barr virus transformation, which may theoretically
contribute to the observed down-regulation of SP140, as SP140
is reportedly involved in mediating virus resistance [26].
Associations between CLL/SLL and several viruses, including
Epstein-Barr virus have been suggested. However, no conclusive
evidence of a causal relationship exists [31].
Figure 1. CLL/SLL susceptibility loci identified through genome-wide association studies. Karyotype depicts CLL/SLL-associated SNPs and
SNPs in LD with those SNPs that were identified through previous genome-wide association studies (GWAS) and follow-up studies. Independent loci
are color-coded with the primary GWAS SNP in dark and SNPs in LD in a lighter shade. Chromosome locations are based on chromosome build 37.1
GRCh37.
doi:10.1371/journal.pone.0029632.g001
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in CLL/SLL
Three SNPs, rs4802322, rs11083846 and rs11670473 were
associated with up-regulation of DACT3, a negative regulator of
Wnt/b-catenin signaling that decreases activation of b-catenin-
responsive genes [32]. Although activated Wnt/b-catenin signaling
may suppress apoptosis in CLL/SLL cells [33,34] and DACT3
inhibits this signaling pathway, our findings suggest that suppression
of Wnt//b-catenin signaling in pre-CLL/SLL cells may increase
susceptibility to CLL/SLL. We also found that rs4802322 and
rs11083846 were associated with increased expression of DACT3
and GNG8. Heterotrimeric G proteins such as GNG8 communicate
extracellular signals received by G protein-coupled receptors to
intracellular effector proteins (reviewed in [35]). GNG8 is involved
in chemokine signaling that controls leukocyte transendothelial
migration and plays a role in several pathways in the glutamatergic,
cholinergic, GABAergic and dopaminergic synapses of the nervous
system (KEGG) [36]. Interestingly, certain G Proteins and G
protein-coupled receptor signaling pathways are associated with
high relapse rate in CLL/SLL patients [37]. Moreover, they have
been implicated in CLL/SLL cell migration [38] and may suppress
apoptosis in CLL/SLL cells [39].
Of those SNPs localized to evolutionarily conserved regions,
only rs11670473 is predicted to alter potential binding sites for
several regulatory elements. Heat shock factors (HSF) and a
putative ‘‘cap’’ binding site may be the most biologically relevant
elements identified. HSF and heat shock proteins are known to
play a role in tumorigenesis [40,41]. Transcription [42] and
mRNA translation [43] are initiated at the cap site. Interestingly,
the cap-binding protein eIF4E and its repressor 4E-BP have been
involved in numerous cancers [44] including CLL/SLL [45].
Although speculative, increased binding of HSF or cap-binding
proteins and up-regulation of DACT3 expression may decrease
Wnt/b-catenin signaling and subsequently render cells susceptible
to CLL/SLL transformation.
In this report we demonstrate that eQTL analysis of existing
GWAS data, in combination with in silico functional predictions, is a
powerful method to identify putative functional risk alleles and to
explore potential causal mechanisms in the etiology of CLL/SLL.
Our data highlight 19 SNPs that influence differential expression of
SP140 a putative tumor suppressor gene, DACT3, a negative
regulator of the Wnt/b-catenin signaling pathway and GNG8,
involved in G-protein coupled receptor and neurotransmitter
signaling pathways. We identified 41 different regulatory elements
that may be involved. Because an association with cancer can be
made for almost any predicted regulatory element, we combined
this method with a comparison of evolutionarily conserved regions
to increase the likelihood of causality. Using this approach, we
selectively identified two putative causal SNPs (rs13384787 and
rs9989746) that influence SP140 and one (rs11670473) that
influences DACT3 expression in association with CLL/SLL risk.
Finally, we were able to identify several transcription factors whose
Table 2. CLL/SLL-associated SNPs that alter gene expression through cis-acting mechanisms.
Differential
gene
expression SNP ID r
2 Chr
Chr Pos
GRCh37 (bp) SNP location
Major/minor
allele Raw P-value
Adjusted P-
value (BH) Expression
SP140 rs6716753 0.95 2 231097129 Intron 1 of SP140 T/C 5.88E-03 0.186 Q
rs6743984 0.95 2 231109329 Intron 5 of SP140 T/C 5.88E-03 0.186 Q
rs7423615 1 2 231116874 Intron 10 of SP140 C/T 1.87E-03 0.114 Q
rs7563433 1 2 231095678 Intron 1 of SP140 T/C 6.10E-03 0.186 Q
rs9989746 0.89 2 231115790 Intron 10 of SP140 G/A 6.72E-04 0.082 Q
rs9989835 1 2 231115630 Intron 9 of SP140 A/T 4.49E-03 0.171 Q
rs9989899 1 2 231114131 Intron 9 of SP140 G/A 1.87E-03 0.114 Q
rs10198539 0.89 2 231105646 Intron 5 of SP140 C/T 8.43E-04 0.086 Q
rs10201872 0.89 2 231106724 Intron 5 of SP140 C/T 6.72E-04 0.082 Q
rs10202244 0.89 2 231106935 Intron 5 of SP140 G/T 6.72E-04 0.082 Q
rs10209615 0.83 2 231089943 Upstream of SP140 T/C 4.66E-04 0.082 Q
rs10498246 1 2 231116417 Intron 10 of SP140 T/A 3.09E-03 0.157 Q
rs13384787 0.89 2 231088084 Upstream of SP140 A/C 6.72E-04 0.082 Q
rs13385151 1 2 231115976 Intron 10 of SP140 C/T 3.75E-03 0.164 Q
rs13397985 - 2 231091223 Intron 1 of SP140 T/G 3.09E-03 0.157 Q
rs28445040 1 2 231110582 Exon 7 of SP140 C/T
c 1.87E-03 0.114 Q
GNG8 rs4802322
a 0.95 19 47242992 Intron 1 of STRN4 A/G 6.63E-03 0.193 q
rs11083846
b - 19 47207654 Intron 5 of PRKD2 G/A 3.34E-03 0.157 q
DACT3 rs4802322
a 0.95 19 47242992 Intron 1 of STRN4 G/A 4.01E-03 0.164 q
rs11083846
b - 19 47207654 Intron 5 of PRKD2 G/A 1.85E-03 0.114 q
rs11670473 0.88 19 47257481 Intron 3 of FKRP G/A 5.01E-03 0.180 q
Notes: Depicted are CLL/SLL-associated SNPs and SNPs in LD that are significantly linked to differential gene expression (BH,0.20). Highlighted in bold are the original
GWAS SNPs and the risk allele, or the minor allele when the risk allele is not known.
a,bSame SNP influencing expression of two distinct genes.
cThe synonymous rs28445040 variation (TCCRTCT) does not lead to a substitution for the serine ([Ser]R[Ser]) at amino acid position 223.
Abbreviations: BH, Benjamini-Hochberg; ChrPos, chromosome position; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma.
doi:10.1371/journal.pone.0029632.t002
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rs13384787, rs9989746 and rs11670473. Experimental studies will
be needed to verify the functionality of the observed eQTL SNPs
and to validate their biological relevance to help unravel the
molecular mechanisms behind these potentially causal associations.
Materials and Methods
Study identification
A literature search of CLL/SLL GWAS and validation studies
was conducted using the electronic database PubMed. We limited
our search to entries on human studies from January 1992 up to
the end of July 2011 (www.ncbi.nlm.nih.gov/pubmed). Our search
strategy used the following keywords: chronic lymphocytic
leukemia/small lymphocytic lymphoma (CLL/SLL) AND poly-
morphisms or single nucleotide polymorphisms (SNPs) AND
genome-wide association (GWA). We searched for any additional
studies in the bibliographies of identified publications, including
review articles. A similar literature search was conducted to find
studies reporting the involvement of an identified regulatory
element with cancer, hematologic cancer or CLL/SLL. We used
the following keywords in PubMed: ‘‘the name of the identified
Figure 2. CLL/SLL-associated SNPs that significantly alter gene expression. Expression quantitative trait loci (eQTL) analysis identified 19
significant CLL/SLL-associated SNPs linked to differential expression of SP140 on chromosome 2 (A), and DACT3 and GNG8 on chromosome 19
(BH,0.20) (B). eQTL SNPs are depicted on a partial chromosome map that includes the differentially expressed gene(s). Chromosome locations are
based on chromosome build 37.1 GRCh37.
doi:10.1371/journal.pone.0029632.g002
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leukemia or chronic lymphocytic leukemia.
CLL/SLL eQTL
For theeQTLanalysis,onerepresentativeSNPperindependently
validated loci was selected (Table 1). The preprocessed and
normalized microarray data [16] corresponding to each of the 60
unrelated European individuals from the HapMap project (Coriell,
Camden, New Jersey, United States) [46] was acquired from the
publicly accessible Gene Expression Omnibus (GEO) database [47]
(http://www. ncbi.nlm.nih.gov/geo; accession number: GSE6536).
SNPs linked to each representative SNP (r
2$0.8) were identified
using the European population (2009-04_rel27) linkage disequilib-
rium files downloaded from the HapMap project website (http://
hapmap.ncbi.nlm.nih.gov). In total, 120 SNPs in the CLL/SLL-
associated loci were then associated with the different genes that had
probes on the microarray platform. Separate analyses to determine
potential eQTL were carried out for each of the probes for a given
gene. Welimited oureQTLanalysisto thedetection of cis-regulatory
regions, whereby the association between a SNP and a gene was
made ifitwaslocated inthepredefined chromosomal rangebetween
300 kb upstream of the transcription start site of the corresponding
gene and 100 kb downstream of the transcription end site of this
gene. This resulted in a list of 613 SNP-gene pairs. The genotype for
each of the unrelated European samples at each SNP location was
obtained from the (2010-08_phaseII+III) genotype files on the
HapMap project website (http://hapmap.ncbi.nlm.nih.gov). The
access of information from the HapMap project files was done in
Java [48]. The top candidates from our eQTL analysis are displayed
inTable2.RiskallelesfortheeQTLSNPsfoundinLDwithoriginal
GWAS SNPs were determined by matching genotype ratios with
those from the original GWAS SNPs.
Statistics
A linear regression between the number of minor alleles (0, 1, or
2) for a given SNP and the associated gene expression for each of
the 60 samples was performed. The P-values obtained from testing
the potential associations between the 613 SNP-gene pairs were
subjected to multiple testing corrections using Benjamini-Hoch-
berg (BH) False-Discovery Rate (FDR) procedure [49]. Associa-
tions were deemed significant at BH,0.20 [50,51]. Linear
regression was done using the javastat package [52] in Java. False
Discovery Rate analysis was done using the multtest package [53]
in the R statistical environment [54].
Bioinformatics
We searched the Kyoto Encyclopedia of Genes and Genomes
(KEGG) database (updated September 20, 2011) [36] for
biological relevant pathways that include the differentially
expressed genes identified in the eQTL analysis. The F-SNP
database [17] (http://compbio.cs.queensu.ca/F-SNP/), which
integrates 16 bioinformatics tools and databases, was used to
predict functional effects on protein coding, splicing regulation,
transcriptional regulation and post translation. Functional signif-
icance scores (FS) are defined by F-SNP, which ranges between 0
and 1. A FS of 0 means none of the tools predict a deleterious
effect; whereas a FS of 1 suggests all tools predict a deleterious
effect. FS were deemed significant if FS$0.5, although it has to be
taken into account that still 45% of disease-related SNPs were
previously found to be ,0.5 [55]. Therefore, SNPs with lower FS
scores were still considered potentially functional when located in
an evolutionarily conserved region (ECR) determined using the
ECR browser (http://ecrbrowser.dcode.org) [21]. Since evolu-
tionarily conserved regions are potentially more likely to indicate
regions of functional importance, we performed a cross-species
sequence comparison of the eQTL SNP target regions, using ECR
browser. Regions overlapping the eQTL SNPs (SNP chromosome
location +/2100 bp) in the human genome (Homo sapiens) were
compared with mouse (Mus musculus) and rat (Rattus norvegicus).
Alignments were considered significant when the evolutionarily
conserved region met predefined length and identity criteria (100
nucleotides and at least 70% identity with either mouse or rat). As
a cross-reference for the transcription factor results within F-SNP,
we used is-rSNP [18] (http://www.genomics.csse.unimelb.edu.
au/product-is-rSNP-service.php) to predict whether any of the
eQTL SNPs would map to a potential transcription factor binding
site. The is-rSNP prediction tool uses the non-redundant human
TF database JASPAR [56] to first determine if any of the two SNP
alleles are significantly predicted to be localized in a potential
transcription factor binding site. This is determined based on
binding scores computed using Position Weighted Matrices for the
chosen transcription factor. For those potential transcription
factors, is-rSNP calculates whether any of the two SNP alleles
significantly alters the binding score. The is-rSNP tool uses a
standard cut-off of P,0.05 for Benjamini-Hochberg [49] correct-
ed P-values of the observed difference between the alleles.
Karyotype
A karyotype displaying the reported CLL/SLL risk loci was
generated using Ensembl release 64 - September 2011, Karyotype
build CRCh37 (http://uswest.ensembl.org/Homo_sapiens/Location/
Genome). Similarly, Ensembl release 64 - September 2011,
Karyotype build CRCh37 was used to generate position overviews
ofsignificanteQTLSNPsonchromosome 2and19.SNP identifiers
were manually added in Adobe Illustrator CS3.
Supporting Information
Table S1 CLL/SLL-associated SNPs in relation to gene
expression. Notes: Depicted are CLL/SLL-associated SNPs and
SNPs in LD (r
2$0.8), which are linked to gene expression.
Highlighted in bold are the CLL/SLL-associated SNPs and SNPs
in LD, which are significantly linked to differential gene expression
(BH,0.20). Abbreviations: BH, Benjamini-Hochberg; Chr Pos,
chromosome position.
(XLSX)
Table S2 Potential cis-acting regulatory elements af-
fected by CLL/SLL-associated SNPs identified by ex-
pression quantitative trait loci analysis. Notes: Depicted are
CLL/SLL-associated SNPs and SNPs in LD that are significantly
linked to differential gene expression (BH,0.20). Highlighted in
bold are the SNPs located in evolutionarily conserved regions and
the risk allele or the minor allele when the risk allele is not known.
a Predicted change in binding score for putative regulatory
element relative to the minor allele.
b Difference P-value:
significance of the change in binding score between the two
SNP alleles, calculated by the is-rSNP tool.
c Adjusted difference
P-value (BH): The Benjamini-Hochberg corrected P-value of the
observed change in binding score between the two SNP alleles,
calculated by the is-rSNP tool (shown are elements with BH-
corrected P,0.05).
d Functional significance score calculated by F-
SNP tool.
e Evolutionarily conserved region based on 100
nucleotides with at least 70% identity, determined using the
ECR browser.
f If present, prior evidence that the predicted cis-
acting regulatory element plays a role in carcinogenesis.
g If
present, prior evidence that the predicted cis-acting regulatory
element is associated with hematologic malignancies.
h If present,
prior evidence that the predicted cis-acting regulatory element is
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CLL/SLL, chronic lymphocytic leukemia/small lymphocytic
lymphoma; CP, cap site; ECR, evolutionarily conserved region;
ESR, exonic splicing regulator; FC, frame shift coding; FS,
functional significance; OG, oncogenic; POG, proto-oncogenic;
SS, splicing site; TF, transcription factor; TS, tumor suppressive.
(DOCX)
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